Browsing by Author "Arias-Loste, Maria Teresa"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Research Priorities for Precision Medicine in NAFLD
    (2023) Iruzubieta, Paula; Bataller, Ramon; Arias-Loste, Maria Teresa; Arrese, Marco; Calleja, Jose Luis; Castro-Narro, Graciela; Cusi, Kenneth; Dillon, John F.; Martinez-Chantar, Maria Luz; Mateo, Miguel; Perez, Antonio; Rinella, Mary E.; Romero-Gomez, Manuel; Schattenberg, Joern M.; Zelber-Sagi, Shira; Crespo, Javier; Lazarus, Jeffrey, V
  • No Thumbnail Available
    Item
    Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)
    (2024) Noureddin, Mazen; Truong, Emily; Mayo, Rebeca; Martinez-Arranz, Ibon; Banales, Jesus M.; Minchole, Itziar; Arrese, Marco; Cusi, Kenneth; Arias-Loste, Maria Teresa; Bruha, Radan; Romero-Gomez, Manuel; Iruzubieta, Paula; Aller, Rocio; Ampuero, Javier; Calleja, Jose Luis; Ibanez-Samaniego, Luis; Aspichueta, Patricia; Martin-Duce, Antonio; Kushner, Tatyana; Ortiz, Pablo; Harrison, Stephen A.; Anstee, Quentin M.; Crespo, Javier; Mato, Jose M.; Sanyal, Arun J.
    Background: Early identification of those with NAFLD activity score >= 4 and significant fibrosis (>= F2) or at-risk metabolic dysfunction-associated steatohepatitis (MASH) is a priority as these patients are at increased risk for disease progression and may benefit from therapies. We developed and validated a highly specific metabolomics-driven score to identify at-risk MASH.